Some non-lawyerly thoughts on the week's price action and Merck's Sotatercept trial
Today's rehearing denial from the PTAB substantially increases Liquidia's 2024 commercialization odds
Finally, $LQDA looks to be on the verge of commercializing a lucrative pulmonary hypertension drug
Who am I kidding? This won't be the last
And other reasons we’re all just pawns in his game
All week I was hoping for major updates across the 3 cases I’m currently covering, but alas, hope is not a strategy. We will have to settle for 1/3…
Weakness on SmartSky patent litigation and SmartSky launch news is a $GOGO buying opportunity
Mudge Zatko’s allegations look more like a hit piece than a real whistleblowing claim
See all

Lionel’s Newsletter